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INTRODUCTION 
 Giant cell tumor is a primary bone tumor. It is benign but locally aggressive 
neoplasm with a tendency for local recurrence. 
 The incidence of giant cell tumor in the Western World is relatively low, 
constituting 5 per cent of all skeletal tumors, however, in the Orient it may account 
for 20 per cent of all primary skeletal neoplasms. It is unknown whether genetic 
differences exist in different races that may account of the high incidence and 
different behaviour of this tumor among the South East Asian population.61 
 In the pre roentgen era, most of these tumors were treated by radical 
amputation. With the invention of X-ray less radical surgery was proposed and 
practiced. 
 The optimum treatment of giant cell tumor of bone is a matter of 
controversy. With the advent of variety of adjuvant and reconstruction techniques 
the recurrence rate has decreased remarkably. But there are no absolute clinical, 
radiological, or histological parameters that accurately predict the tendency of any 
single lesion to recur or metastasize.35 
 
 
 
 Most patients incurring a giant cell tumor of bone are young and active with 
normal life expectancy. The aim of treatment is to remove the tumor completely 
and to preserve the joint. These aims have not changed, but the methods of 
treatment have changed with time. 
 As might be expected, when feasible, curettage with preservation of the 
joint is to be preferred over an en bloc resection, which is associated with a higher 
rate of complications and less satisfactory functional results. 
 Local recurrence is a well documented problem. It is more common after 
simple curettage. 25% of the recurrences were within six months and 97% within 
two years49. 
 
 
 
 
AIM OF THE STUDY 
 This study is aimed at analysing the treatment of the recurrent GCT and 
aggressive GCT with pathological fracture by adequate curettage, using adjuvants 
like H2O2, liquidnitrogen, followed by filling the curetted cavity with bone grafts, 
bone substitutes & bone cement, thereby preventing the recurrence, and to provide 
structural stability in aggressive GCT with Pathological fracture. 
 
 
 
 REVIEW OF LITERATURE 
HISTORY53 
 In ancient times our forebears knew only of malignant tumors. Small benign 
tumors were largely unknown until x-rays revealed them at the turn of the 20th 
century. 
 Sir Astley Cooper and Benjamin Travels described giant cell tumor of bone 
in 1818, emphasizing its essentially benign nature. 
 Herman Lebert (1845) identified the ubiquitous giant cells with the advent 
of microscope and separated giant cell tumors from metastasis lesions to bone and 
other solid tumors of bone that were then generally considered to be osteosarcoma. 
 Sir James Paget called it as a brown or myeloid tumor and gave it classic 
description in 1853. 
 Aguste Nelation (1860) pointed out local aggressiveness of giant cell tumor 
in a monograph. He named this entity as tumor of myeloplaxes, myeloplaxes being 
osteoclastic giant cells according to the then prevalent terminology. 
 Rudolf Virchow (1963 - 1867) described that these tumors may not only 
recur but also eventually turn into a fully malignant tumor. 
Morris (1876) rejected a giant cell tumor from the wrist. 
 Joseph Blood good (1912) named it as Benign giant cell tumor and justified 
 
 
 
the attempt of curetting to preserve function and he was the first to recommend 
phenol treatment of the defect.59 
 Stewart (1822) introduced the term osteoclastoma. 
 Henry L.Jaffe (1896- 1976) in 1940 proposed a histological grading 
system.54 
 Lawson (1952) reported one case of giant cell tumor of the distal radius 
treated with nonvascularized fibular autograft.26 
 Vidal et al. (1969) described the technique of Intralesional curettage 
followed by packing of the defect with PMMA.5,6 
 Person and Waders described the concept of extending the effective margins 
of a curettage beyond its geographic borders with the use of PMMA during mid 
1970's.30 
 Marcove et al. (1970) pioneered the development of cryotherapy in the 
treatment of giant cell tumors of bone and described the effectiveness of the direct 
pour method in freezing the walls of the curetted cavity.30 
 
 
 
 Mario Champanacci proposed a radiographic grading system in 1977.7 
 William F. Enneking (1980) produced a satisfactory staging system for 
musculoskeletal tumors, which was based on clinical, radiological and 
pathological criteria and defined the extent of the surgical procedure to be 
performed to remove the tumor.16 
 Wilkins et al., (1987) reviewed the data of heat effects of PMMA and 
evaluated necrosis in dog model and strongly recommended not to rely upon 
PMMA for tumor control and emphasized the need for thorough curettage with a 
mechanical burr.30 
 Johnston reported the use of H2O2 as a local chemical adjuvant for giant cell 
tumors in 1987.37 
 Schiller et al. (1989) used phenol as a chemical adjuvant and reported 
reduced recurrence rate as compared with surgical resection alone. 
 William F. Enneking (1991) devised a system for the functional evaluation 
of reconstructive procedures after surgical treatment of tumors of musculoskeletal 
system.15 
 
 
 
 NATURE AND GENESIS 
 Giant cell tumor are distinctive neoplasms because they are characterized by 
a profusion of multinuclear giant cells scattered throughout a stroma of 
mononuclear cells. The neoplastic elements are the stromal cells, not the giant 
cells. Giant cells do not persist in cell culture. Neither mitoses nor cellular atypia 
were seen in the culture.47,58 
 Three aspects of these neoplasms are of particular interest.47 
 1. Their cell of origin 
 2. Their differentiation from other giant cell bearing lesions. 
 3. Their biologic behaivour. 
 Studies have used in vitro cell culture techniques to investigate the 
individual cell types present in human giant cell tumors of bone. The goals has 
been to identify and characterize these cells, and to determine their relationship to 
cells of hematopoietic and connective tissue origin.17 
 Three major cell types have been identified based on cell morphology and 
growth characteristics, presence of specific cell surface antigens, presence of 
receptors for hormones and cell products released into the culture medium.17 
 
 
 
 The cell types are: 
 1. Mononuclear cells of monocyte - macrophage origin 
 2. Mononuclear cells of connective tissue origin 
 3. Multinucleated giant cells 
 The giant cells fulfill all the essential criteria for defining osteoclasts: They 
possess abundant calcitonin receptors, which respond to calcitonin with a rise in 
cyclic adenosine monophosphate, and are capable of forming resorption pits on 
bone slices in a manner identical to that of osteoclasts. The giant cells of giant cell 
tumors of bone are also positive for tartrate resistant acid phosphatase and have an 
antigenic phenotype identical to that of osteoclasts. So it can be speculated that the 
neoplastic stromal cells produce some factor, perhaps under the control of 
circulating PTH, which attracts osteoclasts into the tumor or promotes their 
differentiation.3 
 Differentiation of these neoplasms from other giant cell bearing lesion is as 
important as it is difficult. Giant cells are identified as a histologic component of 
the body's reaction to stimulus, provided by a foreign object such as crystalline 
material (monosodium urate), infections (mycobacterium and fungi), abnormal 
levels of hormone (PTH) and neoplasms; of which giant cell tumor is but one, 
where the specific stimulus that provokes the proliferation and accumulation of 
such cells in giant cell tumor is not known. 
 Age group of the patient, location in the bone, radiological features, gross 
 
 
 
and microscopic pathological features are used to differentiate giant cell tumors 
from giant cell rich lesion and neoplasms such as aneurysmal bone cyst, non 
ossifying fibroma, brown tumor etc.46 
 Prediction of the biologic behaviour of giant cell tumors is a challenging 
feature. The natural history of giant cell tumor is one of continued growth and 
local aggressiveness, with extension beyond the cortex into the of tissues. 
Pulmonary metastases may occur and occasionally may spontaneously regress or 
can cause death from pulmonary failure.58 
 
 
 
 CLINICAL FEATURES 
 About 70 to 80 per cent of patients with giant cell tumors are between 20 to 
40 years old, but the tumour is reported in patients from 5 to 73 years of age.28 
Giant cell tumors occurs slightly more often in females than in males. Eighty 
percent of giant cell tumors occurs in the long bones and 75% of these develop 
around the knee joint. 
 
 
 
Presentations of Giant Cell Tumor 
 1. Typical giant cell tumor 
 2. Metastasizing benign giant cell tumor 
 3. Primary malignant giant cell tumor 
 4. Secondary malignant giant cell tumor. 
Typical Giant Cell Tumor 
 Giant cell tumor is typically monostotic with predilection for the ends of 
long bones. The most common sites of involvement are the distal femur, proximal 
tibia and the distal radius, and the skeletal distribution of giant cell tumors of bone 
is shown in Fig.1. A rare polyostotic form of giant cell tumor exist (nearly 30 such 
cases were reported). The multicentric lesions may appear simultaneously or over 
intervals as short as 4 months to as long and 16 years. The histology and 
recurrence rate is similar to that of monostotic giant cell tumor.58 Primary 
mutifocal giant cells tumor of bone, because of its rarity, should be a diagnosis of 
exclusion.34,42 
 Giant cell tumor have been noted to occur in association with paget's disease 
of bone. Most of the cases of giant cell tumor associated with paget's disease have 
bene observed in the head facial bones, spine and the pelvis.39 
 
 
 
 Local recurrence is a well documented problem. Recurrence can be in the 
bone or in the soft tissue. Rate of local recurrence depends on the site (distal radius 
greater than proximal tibia or distal femur) and adequacy of treatment.58 Higher 
rates of recurrence have been noted in tumors of the distal end of radius, tumours 
with pathological fracture and Stage - III tumors according to the classification of 
campanacci.38 
 Goldenberg in his large series stated that 25 per cent of the recurrences were 
within 6 months and 97 per cent with in two years.18 
 The longest interval for recurrence that has bene described was 30 years 
after curettage and bonegrafting. The relative frequency of late recurrence is 1%.49 
Metastazing Benign Giant Cell Tumor 
 Metastasis of the benign giant cell tumor is rare and most metastases are to 
the lungs; Metastases to other sites including brain, kidney, adrenal, gastro 
intestinal tract, other bones, skin, regional lymph nodes, the scalp, and the pelvis 
are extremely rare.26 Histologically the metastases are indistinguishable from the 
primary tumor. Microvascular trauma resulting in tumor embolization at the time 
of curettage can be implicated in most patients. Although it cannot account for 
metastasis occurring before an operation other biological factors, including 
immune surveillance and intrinsic biological characterics of the tumor must be 
operative.4,27 
 The incidence of lung metastases to histologically proven GCT ranges from 
 
 
 
1 per cent to 9 per cent. The mean interval between primary diagnosis and the 
onset of lung metastases was 4.0 years.51 
 Patients who have been managed for benign giant cell tumor of bone should 
be followed at frequent intervals (every 3 to 6 months) with radiographs of the 
chest in conjunction with monitoring for local recurrence.27 
 Patient age or gender is not a risk factor for metastases and also the site of 
original tumor did not influence the rate of metastasis.51 
 It is estimated that there is a six fold increase in the risk of developing lung 
metastases after a local recurrence.51 
 Clinical follow up of reported cases supports good prognosis and long term 
survival13. 
 Inoue et al. reported a case in which 25 nodules of lung metastases were 
excised from the Lt lung and 33 nodules from the right lung. All of these 
metastases were proved histologically to be benign GCT of bone and the patient 
was well  without evidence of recurrence disease with an almost normal lung 
function. So unnecessary over treatment of lung metastases should be avoided and 
therapy should be limited to surgical eradication.13 
 
 
 
Primary Malignant Giant Cell Tumor 
 Primary malignant giant cell tumor exists when a frankly sarcomatous 
lesion is contiguous with a typical histologically benign giant cell tumor.8 
Secondary Malignant Giant Cell Tumor 
 Secondary malignant giant cell tumor results when a sarcoma develops at 
the site of a previously treated giant cell tumor; most of these are due to irradiation 
of the primary tumor.20,33 
 Dahline et al. reported that sarcomatous transformation occurred in 19% of 
patients treated with irradiation, as compared to only 3% of patients treated with 
other modalities.12 
 Data on treatment with orthovoltage radiation along (200 to 250 kilovolts 
peak) have indicated rates of malignant transformation of as high as 25 per cent.2 
 Pooled data from more recent studies on the result of treatment with a 
singed course of mega voltage radiation (approximately forty to seventy gray) 
have indicated a far lower rate of malignant transformation - less than 3 per cent.2 
 The most likely explanation for this difference between ortho voltage and 
mega voltage radiation is attributable to the much higher absorbed dose in bone 
than is indicated by the nominal prescribed dose. This phenomenon results from 
the physics of absorption of low energy photons, particularly the photoelectric 
 
 
 
mechanism whereby energy absorption is directly proportional to the third power 
(Z3) of the atomic number of the tissue. Hence tissues with high Z components, 
such as the calcium of bones, absorbs much more energy per gram of irradiated 
tissue than does muscles. In contrast, with radiation in the mega voltage range, the 
Compton effect dominates and energy absorption is independent of Z. Hence, the 
radiation absorption in muscle, tumor and bone does not vary as it does with the 
lower energy.2 
 The average latency of secondary malignant giant cell tumor is 13 years, 
ranging from 4 yrs to 39 yrs; and 75% are fibrosarcomas and 25% are 
osteosarcomas. Five year survival is 30 per cent; death mostly use to pulmonary 
metastasis.48 
Signs and Symptoms 
 Predominant symptoms are pain and swelling of variable severity. Patients 
may present with decreased joint range of motion or pathological fracture.8,10 
 On physical examination, a tender hard mass in typically found. The skin 
over the swelling may be warm. There may be joint effusion and disuse muscle 
atrophy. Egg shell crackling may be present but it should not be elicited.10 
 
 
 
 Giant cell tumors of the spine (2% to 5%) typically involves only one 
vertebra and have a predilection for vertebral body, kyphosis secondary to body 
collapse may be evident on initial presentation; extension of the tumor into the 
epidural space may produce radicular symptoms and paraplegia.12 
 Giant cell tumors of sacrum (10%) are eccentric and attain large size, but 
rarely produce bowel or bladder dysfunction.12 In pelvis, ilium is the most 
common site affected.50 GCT in children is almost always metaphyseal. 
 
 
 
 INVESTIGATION AND DIAGNOSIS 
 Jaffe first emphasized and Evarts reaffirmed, the triple approach by the 
surgeon, pathologist and radiologist.54 
 It is imperative that the radiologist and pathologist be informed fully of all 
details that is available in order to maximize their contributions. 
Plain Radiograph 
 The conventional GCT appears as a lytic lesion and is eccentrically located 
in epoiphyseo metaphyseal area. It is translucent, lacks stapling or calcification. 
They cross the epiphyseal scar and extend into the metaphysis. Periosteal reaction 
is absent. The radiographic hall mark of this lesion is that it abuts the subchondral 
bone plate of the adjacent joint. There may be progressive thinning and bulging of 
the cortex.46 Perforation of the cortex is found in approximately 25% of patients 
and pathological fracture in 5 to 10% of patients. 8,46 
 Plain radiograph is also useful in the early diagnosis of recurrence.45 Bone 
recurrence usually is evident as an expanding lucency on roentgenogram.8 
Radionuclide Scintigraphy 
 Giant cell tumors produce increased uptake of technetium 99mm 
radiopharmaceutical. It is helpful in evaluating the rare patient with multiple 
lesions.12,46 
Angiography 
 
 
 
 Majority of giant cell tumors are hypervascular but approximately 10 per 
cent may be completely avascular. Vascularity per se does not correlated with the 
clinical course or predict either local recurrence or metastatic potential. It is used to 
determine the relationship of very large tumors to major vessels.12,46 
Computed Tomography 
 Superior to conventional radiograph in outlining tumor extent and cortical 
continuity.12,46 
Magnetic Resonance Imaging 
 Giant cell tumors exhibit signals of low intensity of T1 and high intensity on 
T2 weighted images relative to the bone marrow. Therefore, the intramedullary 
extent is best seen on T1 weighted images, while its extra osseous portion is best 
appreciated on T2 weighted images. 12,21,46 
FNAC 
 It is simple to perform, inexpensive and no morbidity. it is most likely to 
yield a diagnostic sample if the bone lesion is lytic or bad cortical breakthrough or 
soft tissue extension. FNAC has been especially useful in the diagnostic 
confirmation of deep lesions that otherwise are difficult to access. FNAC does 
require clinical, radiographic and pathologic correlation. 1, 14, 60 
 The predictive value of positive result is 100 per cent. So further biopsy is 
unnecessary. A negative result is not highly predictive (71.4 per cent). 
 
 
 
 The risk of needle track contamination of fine needle aspiration biopsy has 
been estimated by Papanicolaou society to be between 3 and 9 per 100,000 
procedures.14,60 
Open Biopsy 
 Advantages of open biopsy include familiarity, provision of more 
histological material and ability to analyse architecture better. If the diagnosis 
offered by FNAC does not fit the clinical and radiographic findings, then open 
biopsy should be considered.60 
Gross pathology 
 The giant cell tumor is solid but often soft and friable. It replaces the bone 
marrow, giving it a brown or reddish appearance. Focal cystic areas, which may be 
composed of aneurysmal bonecystlike tissue grossly and histologically, focal 
yellow areas representing lipid laden macrophges and focal areas of hemorrhage 
and on occasion, necrosis may all be seen. Production of bone is rare.21,47,57,58 
 
 
 
Histology 
 Solid sheet of proliferating mesenchymal cells and multinucleated giant 
cells scattered evenly throughout the lesion. The usual light microscopic 
characteristics used in defining the biologic behaviour of the tumor may be 
misleading in giant cell tumor of bone. 
 Giant cell tumors histologically may vary considerably. They range, at the 
benign end of the spectrum, from aneurysmal bone cysts, chondroblastoma, benign 
fibrous histiocytoma, non ossifying fibroma, brown tumor and giant cell reparative 
granuloma to malignant end of malignant fibrous histiocytoma or even 
osteosarcoma.21,47,57 
 Unni states that ever attempt must be made to diagnose giant cell tumor 
when the clinical picture suggest it, even when the histologic features are 
somewhat atypical.57 
 
 
 
 
 
 
 
 DIFFERENTIAL DIAGNOSIS - GIANT CELL VARIANTS46,54 
 
S. 
No. 
Diagnosis Age Group Location in the 
Bone 
Radiological 
Appearance 
Gross 
pathology 
Microscopic Features 
      Giant Cells Stomal Cells 
1. Giant cell 
tumor 
3rd and 4th 
decade 
Epiphysis or 
metaphysis 
Eccentric 
expanded 
radiolucent area 
Flesh soft tissue Abundant 
innumber, 
uniformly 
distributed. No 
mitosis, no cellular 
atypia 
Plump or poly hedral cells 
with abundant cytoplasm 
and indistinct cell 
membrane 
2. Non Ossifying 
fibroma 
First decade Metaphysis Eccentric oval 
defects 
Flesh soft tissue Focal distribution 
relatively small 
cells with few 
nudei 
Slender, spindle cells with 
little cytoplasm worled 
pattern 
3. Aneurysmal 
bone lyst 
1st and 2nd 
decade 
Metaphysis of 
long bones and 
vertebral column 
Eccentric blown 
out lesions. Soap 
bubble 
appearance 
Cavity filled 
with blood 
Focal around 
vascular channels 
with hemorrhage 
Large vascular channels; 
slender to plump cells. 
Hemosiderin deposition 
4. Brown tumor 
of 
hyperparathy 
radium 
Any age Any where in 
bone 
Subperiosteal 
subchondral and 
sub ligamentous 
resorption of bone
Fleshy tissue 
with cystic 
spaces 
Focal around 
hemosiderin 
pigment 
Fibrous stroma with slender 
spindle cells 
5. Simple bone 1st and 2nd metaphysis Trabeculation in Cyst field with Focal around Cyst wall of fibrous tissue 
 
 
S. 
No. 
Diagnosis Age Group Location in the 
Bone 
Radiological 
Appearance 
Gross 
pathology 
Microscopic Features 
      Giant Cells Stomal Cells 
cyst decade radiolucent area clear fluid cholesterol crystals and metaplastic bone 
6. Chondro 
blastoma 
2nd decade Epiphysis Radiolucency 
with spotry 
opacities 
Firm to Fleshy 
tissue 
Few and Focal Plump round or ovoid cells 
with pericellular 
calcification 
7. Fibrous 
dysplasia 
1st and 2nd 
decade 
Metaphysis Ground glass 
appearance 
Firm and Gritty Few and Focal Woven bone and whorled 
fibrous tissue, no 
osseoblasts, 
8. Giant cell 
reparative 
granuloma 
2nd and 3rd 
decade 
Maxila and 
mandible 
Radiolucent focus Soft fleshy tissue Focal around 
haemosiderin 
pigment or 
hemorrhage 
Slender or Plump spindle 
cells 
9. Ossifying 
fibroma 
2nd and 3rd 
decade 
Maxilla and 
mandible 
Radiopaque Firm and Gritty Few and Focal Lamellar bone, trabeculae 
in fibrous tissue, 
osteoblastic rimming 
10. Osteosarcoma 2nd and 3rd 
decade 
metaphysis Radiolucent or 
dense 
soft, firm or hard Focal distribution Malignant cell with direct 
osteoid formation 
11. Chondromyox
oid fibroma 
2nd and 3rd 
decade 
Metaphysis Eccentric, 
expanded, lytic 
Soft to firm focal distribution Chondroid, myxoid and 
fibrous lobules 
12. Osteoblastoma 2nd and 3rd 
decade 
Diaphysis of long 
bones and 
vertebral column 
Radiolucent or 
dense 
Haemorrhagic 
and gritty 
Focal Distribution Abundant osteoid with 
osteoblast 
 
 
 
  
 STAGING 
 Staging is the process of classifying a tumor, with respect to its 
degree of differentiation as well as its local and distant extent, based on 
clinical, radiographic and histological features in order to estimate the 
prognosis of the patients. 
 Grading represents an estimation of the likelihood of metastasis 
based on histological measures of cell differentiation and growth.40 
  
 HISTOLOGICAL GRADING SYSTEM 
 OF JAFFE et al25,24 
Grade I - Completely benign 
 Showing moderately loose vascular stroma composed of spindle and 
ovoid cells with few or no mitotic figures and numerous giant cells. 
Grade II - Borderline 
 Showing cytologically a very compact cellular stroma showing 
definite evidence of atypia, tend strongly towards recurrence and in some 
cases - eventually undergo malignant transformation. 
Grade III - Frankly Sarcomatous 
 Showing a compact stroma in which stromal cells are universally 
pleomorphic and the giant cells are smaller and less numerous and generally 
metastasis. 
 Jaffe and Huvos intend to relate histological features with the clinical 
course and to predict the outcome. But this system has no prognostic value 
and no correlation with recurrence rate.22,25,52 
  
 CAMPANACCI – RADIOGRAPHIC GRADING SYSTEM7 
 Both primary and recurrent tumors graded radiographically, based on 
margins of the lesion. It is more reliable than histologic grading, predicts 
tumor behavior, especially recurrence. 
Grade I - Intraosseous lesion 
 Tumor with well marginate border of mature bone and cortex intact 
or slightly thinned but no deformed 
Grade II - Intraosseous lesion with cortical thinning 
 Tumor with relatively well defined margin without radiopaque rim. 
Grade III - lesion extending extraosseously 
 Tumor with fuzzy borders, suggesting a rapid and possible 
permeative growth. 
  
 ENNEKING STAGING8,16 
 Enneking has proposed a staging system for giant cell tumors based 
on clinical, radiological and pathologic criteria. 
Stage 1 - Latent 
 10 to 15% of patients, virtually symptomatic often discovered 
incidentally, occasionally may cause pathological fracture, has sclerotic rim 
on roentgenographic or CT evaluation is relatively inactive on bone scan 
and is histologically benign. 
Stage 2- Active 
 70% of patients; symptomatic, often associated with pathologic 
fracture, has expanded cortex but no break through, is active on bone scan 
and is histologically benign. 
Stage 3 - Aggressive 
 10% to 15% of patients, symptomatic, rapidly growing mass, has 
cortical perforation with accompanying soft tissue mass, activity on bone 
scan extends beyond the lesion seen on roentgenogram, shows intense 
hypervasculavity on angiogram but is histologically benign. 
  METHODS OF TREATMENT 
 Treatment of recurrent lesions is the same as for primary lesions. 
After biopsy shows that the tumor is still benign, repeat curettage or 
resection should be performed. 
 The method of treatment include intralesional curettage, using 
adjuvants like, liquid nitrogen. Hydrogen peroxide, and filling the cavity 
with bonegrafts, bone substitute and some cement. 
The available methods of treatment 
1. Intralesional excision 
 a. Curettage only 
 b. Curettage with bone grafting 
 c. Curettage with bone cementing 
 d. Extended curettage 
2. En bloc resection 
 a. En bloc resection only 
 b. En bloc resection with reconstruction 
 c. En bloc resection and custom arthroplasty 
 d. En bloc resection and arthrodesis 
3. Amputation 
 4. Radiotherapy 
1. Intralesional excision 
 An intralesional procedure passes through the pseudocapsule of the 
neoplasm directly into the lesion. Macroscopic tumor remains and the entire 
operative field is potentially contaminated. Curettage is an intraleional 
procedure. High speed burr can be used after curettage to decrease the local 
recurrence rate.31 
a. Curettage Only 
 Curettage alone is less successful because surgeons will be less 
vigorous when only utilizing curettage in order to diminish the chance of 
post operative fracture and high incidence of local recurrence will be the 
result (75%).12 
b. Curettage and bone grafting 
 Indicated for giant cell tumors of proximal humerus, distal radius, 
distal tibia and small bones, because there are no effective arthroplasty 
salvage procedures available in these area. If the articular surface 
deteriorates fusion is indicated which requires bone stock restoration. 
 This procedure has a recurrence rate of about 40 per cent.52 
c. Curettage and bone cementing 
  Packing with cement after curettage of a giant-cell tumor has been 
advocated for many reasons.38 
• Provides immediate support and allows for intensive curettage even 
of large tumor cavities. 
• The contrast between barium - impregnated cement and the bone 
makes radiographic detection of a local recurrence easier.40 
 Most specific radiological sign of recurrence is lysis of 5mm of more 
at the cement bone interface. This precedes clinical signs by a mean of 4 
months. When there is an complete sclerotic margin around the cement 
there will not be any recurrence.45 
• If recurrence occurs, other therapeutic options still exist. 
• Possible direct toxic effect of the monomer on tumor cells. 
 Wilkins et al., recommended not to rely upon hyperthermia of 
PMMA polymerization for tumor control which never exceeds 46C while 
the bone marrow necrosis occurs at or above 60C. 
 Subchondral PMMA is tolerated because cartilage derives its 
nutrition from synovial fluid. 
 With this procedure, the rate of local recurrence is 9 to 14 per cent. 
d. Extended Curettage 
  Adjuvants such as phenol, liquid nitrogen and H2O2 can be used with 
any of the above mentioned intralesional procedures to decrease the local 
recurrence. 
2. En bloc resection 
 A wide excision, commonly termed en bloc resection, includes the 
entire tumor, the reactive zone and a cuff of normal tissue. This is an 
intracompartmental procedure and may leave skip lesion. Usually requires 
sacrifice of the articular surface, so impairs the joint function. En bloc 
resection is effective in the prevention of recurrence, with rates ranging 
from 0 to 32 per cent.11 
a. En bloc resection only 
 It is recommended for giant cell tumors of expendable bones such as 
proximal radius and fibula, distal ulna, tubular bones of hand and foot, 
coccyx, sacrum and pelvic bones. 
b. En bloc resection with reconstruction 
 Commonly recommended for giant cell tumors of the distal radius 
multiple and rapid recurrences of GCT and displaced intra articular 
pathological fractures. 
  Method of reconstruction after en bloc resection of distal radius can 
be with: 
 1. Allogenic transplantation of the distal radius. 
 2. Iliac crest autograft. 
 3. Non-vascularized proximal fibular autograft. 
 4. Vascularized proximal fibular autograft. 
c. En bloc resection and custom made arthroplasty 
 For the uncommon elderly patients with an extensive giant cell 
tumor, a massive endoprosthesis would be a consideration. However 
because of the high incidence of late loosening, such reconstruction is not 
preferred for younger patients. 
d. En bloc resection and arthrodesis 
 Arthrodesis should be reserved for salvage of a failed arthroplasty. If 
more than 50% of the articular surface is destroyed a primary fusion is 
considered.59 
 Primary arthrodesis of wrist may be considered for patients who do 
heavy manual labour.9,24 
 Amputation 
 Amputation is reserved for massive recurrence, malignant 
transformation or infection.31,41 
4. Radiotherapy2,21 
 Megavoltage radiation therapy administered in single course (50 to 
60 gray). 
Indications 
1. When patient can not be operated on for medical reasons. 
2. When a tumor is technically inoperable - axial skeleton & skull. 
3. When an operation would result in major and unacceptable 
disfigurement. 
 ADJUVANTS - THEIR MECHANISMS OF ACTION AND 
COMPLICATION 
1. Liquid Nitrogen - Cryosurgery29,30,31,32,36 
 Extreme cold is used to produce tissue necrosis 
 Temperatures between - 21 to - 60 are needed to obtain cellular 
necrosis, temperatures below -60 exert no further lethality. 
 The following mechanism underlie cellular injury at subzero 
temperatures. 
 1. Thermal shock 
 2. Dehydration and toxic effects of electrolyte changes 
 3. Formation of intra cellular ice crystals and membrane 
disruption - most important mechanism. 
 4. Denaturation of cellular proteins. 
 5. Micro vascular failure - most likely cause of late 
complications. 
 Function involved in the spread of freezing and subsequent necrosis 
are 32 
 1. Density and vascularity of bone 
  2. Presence or absence of tourniquet 
 3. Size and temperature of the heat sink 
 4. Duration of freeze, and 
 5. The presence of cryoprotective molecules. 
Limiting factors of cryosurgery are32 
1. Size usually 5 inches is the maximum diameter capable of being 
adequately frozen and therefore necrotized. 
2. When a tumor spilled into a joint, an en bloc resection would be 
preferable. 
 Marcove et al., described a direct pour technique in which liquid 
nitrogen is poured directly into a curetted tumor cavity instead of being 
introduced through the closed system.23 This method has the advantage of 
increasing the contact of the coolant with the irregular was of a curetted 
cavities. 
Rapid freeze and slow thaw cycle is recommended30 
 Rapid freeze causes intracellular ice crystals to form, whereas slow 
freeze causes cellular dehydration. Conversely, a slow thaw will cause 
intracellular crystallization and membrane disruption, whereas a rapid thaw 
will not. This is explained by the physics of crystallization. If there is slow 
warming, the numerous intracellular crystals will recrystallize into a few 
 large crystals that will damage the cell membrane upon fast warming, the 
intracellular crystals will melt before they can damage the cell. 
 Repeated freeze thaw cycles will also increase the extent of necrosis. 
this is due to increased conductivity of cold after the first freeze. 
 Marcove et al. stated that three freeze and thaw cycles produce tumor 
cell death upto 2 cms from the cavity margin. 
Advantages 
 1. The rate of local recurrence is around 4 per cent 
 2. Preservation of adjacent joint 
 3. Avoidance of the need for extensive reconstruction by 
prosthetic replacement, allograft or arthrodesis. 
Disadvantages 
 1. Wound problems - 5 to 10% 
 2. Late pathological fracture - 11 to 28% 
 3. Transient neuropraxia 
2. PHENOL6,12,56 
 Phenol solution eliminates the remaining cells by non-specific 
coagulation necrosis, and DNA damage. 
  The reported concentration of phenol solution used for this purpose 
varies from 5% to 75%. 
 Curetted cavity should be filled with pure liquid phenol for 30 to 45 
seconds. After removal of the phenol, the cavity is rinsed with 75 to 85% 
alcohol, the alcohol residue is then removed by vigorous saline lawage. 
Advantage 
 1. Reduced penetration of phenol causes one to one and half a 
millimeters of bone injury and reduced rate of fracture. 
 2. High rate of cure and preservation of adjacent joint 
Disadvantages 
 Phenol is toxic to the nervous system, the heart, the kidneys and the 
liver and is readily absorbed through skin, mucosa and open wounds.6 
 The use of concentrations higher than 5 per cent is hazardous and the 
lethal dose in 1gm.56 
3. Hydrogen Peroxide37,55 
 Johnston first reported the use of H2O2 as a local chemical adjuvant 
for giant cell tumors. 
 H2O2 causes cell death by inhibiting lactate production in tumor cells. 
  Cell death occurs at concentration of 30mm H2O2 which is 
substantially lower than the 3% (880mm) H2O2 commonly used clinically. 
 In a follow up series of 38 patients treated with curettage, H2O2 
adjuvant and bone cementing, the recurrence rate was 8%. 
 There have been no reported negative clinical effects of exposure to 
H2O2. 
 
  MATERIALS AND METHODS 
 This study was conducted between Aug 2003 to Feb  2006, of which, 
10 cases of Aggressive GCT with pathological fracture and 10 cases of 
recurrent GCT was done. In the cases of Aggressive GCT with Pathological 
fracture, the bone was structurally unstable and had to be mechanically 
stabilized. Mere cortical breach does not qualify for this criteria. 
 Recurrent GCT - 10 Cases 
SITE 
Distal Femur 3 
Proximal Tibla 3 
Proximal fibula 1 
Distal Radius 2 
Meta carpal bone 1 
 
SEX 
Sex No. of Cases 
Male 6 
Female 4 
 
 AGE INCIDENCE 
10-20 20-30 30-40 
1 7 2 
 
STAGING ENNEKING SYSTEM 
 Stage – 2 
 
 
Treatment Methods 
 Removal of bone cement, extended curettage, and bone cement - 3 
cases. 
 Extended curettage with bone cement - 3 Cases. 
 Curettage & bone grafting - 2 Cases. 
 Amputation with adjuvant usage -1 Case. 
 Further Resection and Adjuvant used -1 Case. 
 Tourniquest used in all cases. Blood transfusion was not used in any 
of these cases. 
 Aggressive GCT with Pathological fracture 
Site 
Distal Femur 7 
Proximial Tibia 3 
 
Sex 
Sex No. of Cases 
Male 3 
Female 7 
 
Age incidence 
10-20 20-30 40-50 
4 5 1 
 
Staging Enneking 
 Stage 3 
Treatment Method 
 Extended curettage with adjuvants H2O2/ liquid nitrogen and 
reconstruction with Fibular Strut graft, cancellous bone graft/ bone 
substitute/ bone cement. 
 SURGICAL TECHNIQUE 
 Intra lesional excision with extended curettage, adjuvant hydrogen 
per oxide and reconstruction with bone graft/bone substitute/bone cement. 
  Patient in supine position under regional or general anaesthesia, 
tourniquet (without exsanguination) was used during the procedure to 
decrease local bleeding and prevent blood from acting as a heat sink and 
being a barrier for the cryotherapy. Electrocautery was used on all soft 
tissue dissection because it potentially extends the margin of tumour kill. 
Violation of the joint cavity avoided to prevent the possibility of 
contamination of the joint cavity with tumor cells and potential injury to the 
cartilage after direct exposure of liquid nitrogen. 
 Out of 10 cases with pathological fracture, seven were in distal femur 
and three in proximal tibia, after exposure, a large elliptical cortical window 
with its axis parallel to the long axis of the bone was made to reduce the 
stress raising effect, on the side of maximum involvement and breach. 
Adequate window was made and the cavity was curettaged thoroughly. 
Hydrogen peroxide was used as adjuvant in 9 cases and liquid nitrogen in 
one case. 
 Before introduction of liquid nitrogen, bone perforations were 
identified and sealed. The surrounding skin, soft tissues and neuro vascular 
structures were protected. Large skin flaps were retracted to protect them 
from any possible spillage of the liquid nitrogen. 
 The direct pour (open) technique as described by Marcove et al. was 
used. Liquid nitrogen was poured through a stainless steel funnel into the 
tumor cavity, and care was taken to fill the entire cavity. The surrounding 
 soft tissues were irrigated with saline solution to decrease the possibility of 
thermal injury. Two freeze and thaw cycles were administered. In each 
cycle, liquid nitrogen was left in the cavity until it had evaporated 
completely. Spontaneous thaw was allowed to occur for 3-5 mts. After 
evaporation, the cavity was irrigated with saline. Reconstruction was 
performed with poly methyl methacrylate. 
 In patients where hydrogen per oxide was used as adjuvant, undiluted 
Hydrogen peroxide was used 3 times with a holding time of 3mts. each 
time. When sub-chondral bone is thinned or absent, cancellous bone 
harvested from iliac crest mixed along with bone substitutes (G-bone) were 
packed to a thickness of 3-5mm. Then fibular strut graft was placed across 
the fracture site longitudinally. If there was an inter-condylar fracture of 
distal femur, the strut was placed transversely and the cavity filled with 
bone cement. 
 In 10 cases of recurrent GCT, that we managed, three occurred in 
proximal tibia following curettage and bone cementing without any 
adjuvant, 3 occurred in distal femur following curettage and bone grafting 
without any adjuvant, One in proximal fibula following enbloc resection, 
another in metacarpal bone following enbloc resection and reconstruction 
with fibular graft and two in distal radius following curettage and bone 
grafting. 
 For proximal tibial recurrence the cement was removed and extended 
 curettage was done using hydrogen peroxide and fixed again with bone 
cement. For distal femur recurrence, extended curettage with adjuvant H2O2 
was done and cavity filled with bone cement.  Proximal fibula where 
resection was done previously, further segment of bone was resected and 
hydrogen peroxide was used to prevent recurrence. 
 In the case of second meta carpal bone recurrence, second ray 
amputation was done and hydrogen peroxide was used. Recurrence in distal 
radius was managed with extended curettage using hydrogen peroxide and 
bone grafting. 
 Fresh instruments, an additional layer of surgical drapes and new 
surgeon gloves were used to complete surgery after the tumor resection and 
adjuvant treatment. Wound closed with suction drain insitu. 
Post operative management and follow-up 
 Routine antibiotics were administered for 5-7 days, the drain was 
removed after 48 hrs and wound was examined. 
 For the patients with pathological fracture, the limb was protected in 
a removable brace for six weeks with intermittent gentle passive 
mobilization done under strict supervision. After six weeks the brace was 
removed, full mobilization was started and gradual weight bearing allowed 
only after radiological evidence of union, which was between 10-12 weeks. 
 For the patients with recurrent GCT, the wound was examined on the 
 third day after surgery, if the skin was intact, passive and active motion of 
the adjacent joint was begun. Weight bearing allowed with support after 72 
hrs. 
 Roentgenogram of the tumor site and the chest at 3 months intervals 
for 1 year, at 6 month interval for the following 2 year, and annually 
thereafter was taken to detect local recurrence and pulmonary metastases. 
  
SCORING SYSTEM 
 The outcome was graded according to the scoring system of 
william.F.Enneking15. 
 In brief the system assigns numerical values (0-5) for each six 
categories. Pain, function and emotional acceptance in the upper and lower 
extremities; supports, walking ability, and gait in the lower extremities; and 
hand positioning, manual dexterity and lifting ability in the upper limb 
(Appendix). 
 OBSERVATION & RESULTS 
 10 cases of Recurrent GCT and 10 cases of Aggressive GCT with 
pathological fracture were studied. 
 Out of 10 recurrent lesions, in three patients proximaltibia, in three 
patients distal femur, in two patients distal radius, in one patient 
proximalfibula and in one patient metacarpal bone were affected. 
 Out of 10 Aggressive GCT with pathological fracture in 7 patients 
distal femur and in three patients proximal tibia were affected. 
 For recurrent GCT, removal of bone cement, extended curettage with 
adjuvant Hydrogen peroxide and reconstruction with bone cement/ born 
graft/ amputation were the treatment methods employed. 
 For Aggressive GCT with pathological fracture, extended curettage 
with adjuvant H2O2/ liquid nitrogen and reconstruction with fibular strut 
graft cancellous bone graft, bone substitute and bone cement were the 
treatment methods employed. 
 The results were assessed with the scoring system proposed by 
Enneking. 
 Scoring After Surgery in Lower Extremely 
Factor No. of patients 
Maximum 
attainable 
score 
Total score Rating percentage 
Pain 17 85 82 96 
Function 17 85 51 60 
Emotional 
Acceptance 
17 85 68 80 
Support 17 85 70 82 
Walking 
ability 
17 85 75 88 
Gait 17 85 70 82 
Average    81.3 
 
Scoring after surgery in upper extremity 
Factor No. of patients 
Maximum 
attainable 
score 
Total score Rating percentage 
Pain 3 15 15 100 
Function 3 15 14 93 
Emotional 
Acceptance 
3 15 14 93 
Hand Positioning  3 15 14 93 
Manual dexterity 3 15 14 93 
Lifting ability 3 15 13 86 
Average    93 
 The average follow up was 2 years.  
  Two patients had superficial wound infection, healed well with 
antibiotics. 
 There was no neurovascular complications, malignant change, 
recurrence, pathological fracture and metastasis. 
 Radiologically there was no lysis at cement bone interface. 
 The average rating percentage for patients after surgery in lower 
extremity was 81.3 
 The average rating percentage for patients after surgery in upper 
extremity was 93. 
  DISCUSSION 
 Though historically it is believed that GCT occurs more commonly in 
females21, there are other series which reported male predominance. 
C.R.R.M Reddy et al. reported 64% in males44, and H.N. Sung et al. 
reported 56% in males.52 
 The factors that would have led to recurrence were inadequate 
curettage and lack of extended curettage with adjuvants. 
 Local recurrence is a well documented problem. It has been as 
frequent as 50% after simple curettage and 7% after excision with curettage, 
0% after wide or radical resection. A report of a large series stated that 25% 
of the recurrences were within 6 months and 97%, within 2 years. Some 
authors have reported that all recurrences were within three years. But 
others have reported recurrences after six years, ten years, 12 years and 
thirteen years.49 
 In this study we treated 10 cases of Aggressive GCT with 
pathological fracture and 10 cases of Recurrent GCT. 
 Simple curettage or curettage with bonegrafting resulted in 
recurrence from 30 to 80%.52 Various adjuvants such as electro-cautery, 
phenol, liquid nitrogen, hydrogen peroxide have reduced the recurrence rate 
to 10%.55 
 Jonston in 1987 first reported the use of hydrogen peroxide in GCT.37 
 Hydrogen peroxide is preferred over other adjuvants because it is less toxic 
to surrounding tissues, has the same efficacy in terms of preventing 
recurrence55 and in vitro studies have demonstrated that in lesser 
concentration, it produces cell lysis and death.37 
 Patients presenting with pathological fracture and loss of cortical 
bone support of less than 50% of the cross sectional area of the bone, 
extended curettage with PMMA reconstruction is suggested59. Sung et al 
described a procedure of excision and curettage in such cases where the 
main bulk of tumor is excised, retaining the articular cartilage covered by a 
thin shell of bone and then remaining cavity curetted. In their 12 cases they 
have not had any recurrence52. 
 Other forms of treatment like massive allograft construction has 
increased chance of infection, fracture and recurrence. In patients with GCT 
occurring in third decade having otherwise normal lifespan, if constrained 
endo-prosthesis is used, they will develop early loosening and loss of bone 
stalk. They will require a very complicated salvage procedure within a very 
short span of time. 
 We report 10 cases of aggressive GCT with pathological fracture 
with more than 50% of cortical bone involvement treated by partial excision 
and reconstruction with fibular strut graft and bone cement. All had good 
functional range of motion with an average flexion of upto 100o and full 
weight bearing on an average of 4.5 months following surgery. 
  PMMA acts as a filler and provides immediate stability to the bone 
but it does not act as an adjuvant in reducing the rate of recurrence.55 
Recurrence occurred following reconstruction with bone cement without 
using adjuvant. We removed the bone cement and the cavity was 
currettaged following by bone cementing. 
 Enbloc resection resulted in similar or more recurrence than 
curettage, probably because of higher radiological grade or local tissue 
contamination. We had 2 cases of recurrent GCT out of 9 cases of enbloc 
resection which were done without using adjuvant. They were managed 
with a proximal resection and hydrogen peroxide was used as an adjuvant. 
Two cases of distal radius where curettage and bone grafting resulted in 
recurrence, we did an extended curettage using hydrogen peroxide and bone 
grafting. 
  
CONCLUSION 
 GCTis a locally aggressive benign tumor occurring in young 
individuals with a normal life expectancy. If inadequately or inappropriately 
treated it results in considerable morbidity and recurrence. 
 Careful attention to soft tissue protection while using cryosurgery 
significantly decreased the previously published reports of high rates of 
infection and wound healing problem. 
 Hydrogen peroxide is an ideal adjuvant, which gives a comparable 
rate of recurrence and least local or systemic complications. Free fibular 
strut graft along with PMMA incorporates in the bone early and the joints 
can be salvaged with useful function. Enbloc resection must also be 
followed by adjuvant to prevent recurrence due to local tissue 
contamination. 
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  APPENDIX 
 
ENNEKING SCORING 
CRITERIA FOR EITHER EXTREMITY 
PAIN  
 
No. Description Date 
5. No pain No medication 
4. Intermediate  
3. Modest/ non disability Non-morcotic 
analgesics 
2. Intermediate  
1. Moderate/ intermittently disabling Intermittent narcotics 
0. Sever/ Continuously disabling continuous narcotics 
 
Function 
 
No. Description Date 
5. No restriction No disability 
4. Intermediate  
3. Recreational restriction Minor disability 
2. Intermediate  
1. Partial occupational restriction Major disability 
0. Total occupational Complete disability 
 Emotional acceptance 
 
No. Description Date 
5. Enthused World recommend to Others 
4. Intermediate  
3. Satisfied Would do again 
2. Intermediate  
1. Accepts Would repeat reluctantly 
0. Dislikes Would not repeat 
 
CRITERIA SPECIFIC FOR THE LOWER EXTREMITY 
 
Supports 
 
No. Description Date 
5. None No supports 
4. Intermediate Occasional use of brace 
3. Brace Mostly branch 
2. Intermediate Occasional cane/ Crutch 
1. One cane or Crutch Mostly cane/ Crutch 
0. Two canes/ Crutches Always Canes Crutches 
 
Walking ability 
 
No. Description Date 
5. Unlimited Same as Preoperative 
4. Intermediate  
3. Limited Significantly less 
2. Intermediate  
1. Inside only Cannot walk outside 
0. Not independently Can walk only with assistance or 
whell chair bound 
 Gait 
 
No. Description Date 
5. Normal No alteration 
4. Intermediate  
3. Minor cosmetic Cosmetic alternation only 
2. Intermediate  
1. Major cosmetic Minor functional deficit 
0. Major handicap Major functional deficit 
 
 
CRITERIA SPECIFIC FOR THE UPPER EXTREMITY 
 
Hand Positioning 
 
No. Description Date 
5. Unlimited 180 elevation 
4. Intermediate  
3. to above shoulder or no 
prosupination 
90 elevation 
2. Intermediate  
1. Not above wrist 30 elevation 
0. None 0 elevation 
 Manual dexterity 
 
No. Description Date 
5. No limitations Normal dexterity and 
sensitibility 
4. Intermediate  
3. Loss of fine movements CAN NOT BUTTON TC OR 
MINOR LOSS OF 
SENSITIVITY 
2. Intermediate  
1. Can not pinch Major sensory loss 
0. Can not grasp Anesthetic hand 
 
Lifting ability 
 
No. Description Date 
5. Normal load Matches normal 
4. Intermediate Less than less Normal 
3. Limited Minor load 
2. Intermediate Gravity only 
1. Helping only Can not over come gravity 
0. Can not help Can not move 
 
 
 
 
 
 
 
 
 
  
 MASTER CHART 
 RECURRENT GCT 
 
S. 
No 
Name Age & 
Sex 
Location of 
tumor 
Time to 
recurrence 
Initial 
Procedure 
Diagnosis 
Confirmed 
by 
Substitute Procedure Adjuvant 
used 
Type of 
Anaesth
esia 
Duration of 
followup 
Status at 
followup 
1. Rambabu 26/M Left proximal 
tibia 
2 Months Curettage & 
Bone cement 
FNAC Cement Removal 
Extended curettage 
and bone cement  
H2O2 SA 2 Years & 4 
Months 
Disease free 
2. Yesiah 23/M Left proximal 
tibia 
2 Months Curettage & 
bone cement 
FNAC Cement Removal 
Extended Curettage 
with Bone Cement 
H2O2 SA 2 Years & 4 
Months 
Disease free 
3 Palani 33/M Left distal 
femur 
3 Months Curettage & 
bone grafting 
FNAC Extended Curettage 
with Bone Cement 
H2O2 SA 2 Years & 4 
Months 
Disease free 
4 Vasantha 17/F Right distal 
femur 
4 Months Curettage & 
bone grafting 
FNAC Extended Curettage 
with Bone Cement 
H2O2 SA 2 Years  Disease free 
5 Gunasekaran 31/M Left distal 
femur 
2 Months Curettage & 
bone grafting 
FNAC Extended Curettage 
with Bone Cement 
H2O2 SA 2 Years  Disease free 
6 Dillikumar 29/M Left distal 
radius 
2 Months Curettage & 
bone grafting 
FNAC  Extended curettage 
with bone grafting 
H2O2 GA 2 Years  Disease free 
no lung 
metastases 
7 Parimala 27/F Right Proximal 
fibula 
2 Months Resection FNAC Extended Curettage 
Resection 
H2O2 SA 2 Years  Disease free 
8 Murugan 25/M Right distal 
radius 
2 Months Curettage & 
bone grafting 
FNAC Extended Curettage 
with Bone grafting 
H2O2 GA 2 Years  Disease free  
no lung 
metastases 
9 Kokila 25/F Left Proximal 
tibia 
2 Months Curettage & 
bone cement 
FNAC Cement removal 
Extended Curettage 
with Bone Cement 
H2O2 SA 2 Years  Disease free 
10 Lalitha 23/F Left II 
Metacarpal 
bone 
2 Months Enbloc resection 
with fibular strut 
reconstruction 
FNAC II Ray amputation 
with adjuvant 
H2O2 GA 2 Years  Disease free  
  
 MASTER CHART 
 
 AGGRESSIVE GCT WITH PATHOLOGICAL FRACTURE 
 
S. 
No 
Name Age & Sex Location of tumor Duration of 
Symptoms 
Diagnosis 
Confirmed by 
Procedure done Adjuvant 
used 
Type of 
Anaesthesia 
1. Kotteswara rao 30/M Left Lateral condyle 
of Femur 
8 Months FNAC Extended Curettage 
Fibular Strut Graft 
cancellous bone graft `G' 
bone & bone cement 
H2O2 SA 
2. Helena 17/F Left proximal tibia 6 Months FNAC Extended curettage, 
fibular strut graft, 
cancellows graft, `G' 
bone and Bone cement 
H2O2 SA 
3 Visalatchi 19/F Left distal femur 8 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
4 Parimala 27/F Left proximal tibia 6 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
5 Meganathan 29/M Right Medial 
Condyle of Femur 
6 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
6 Raghu 18/M Left distal end of 
femur 
6 Months FNAC Extended Curettage  
bone cement 
H2O2 SA 
7 Logeswari 36/F Left Lateral Condyle 
of femur 
6 Months FNAC Extended Curettage  
bone cement 
Liquid 
phenol 
SA 
8 Jayalakshmi 30/F Medial Condyle of 
Femur 
6 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
9 Sangetha 17/F Medial Condyle of 
Femur 
6 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
10 Devi 27/F Right Proximal tibia 6 Months FNAC Extended Curettage with 
Bone Cement 
H2O2 SA 
  
 
  PROFORMA 
 
Name      Hospital No. 
 
Age       Sex 
 
Address 
 
Occupation 
 
Date of Presentation 
 
Symptoms and Signs 
 
 1. Pain and its characters 
 
 2. Swelling 
 
 3. Limp 
 
 4. Limitation of joint movements 
 
Site and Side involved 
 
history of Injury 
 
Date of follow up 
 
Classification (Enneking) 
 
Stage 1 - Latent 
 
Stage 2 - Active 
 
 Stage 3 - Aggressive 
Diagnosis confirmed by 
 
 1 FNAC - 2 Open Biopsy 
 
Methods of Treatment 
 
 For recurrent Gct: removal of bone cement, extended curettage with 
adjuvant Hydrogen peroxide/ liquid nitrogen and reconstruction with bone 
graft/ bone substitute/ bone cement. 
 
 For Aggressive GCT with pathological Fracture - Extended curettage, 
and reconstruction with bone graft/ bone substitute/ bone cement. 
 
Post operative protocol 
 
 1. Drain removal at 48 to 72 hours 
 
 2. Non-weight bearing mobilization after 72 hours 
 
 3. For recurrent GCT, passive and active mobilization of adjacent 
joint was started after 3 days. Weight bearing with support after 6 weeks. 
 
 4. For aggressive GCT with pathological fracture limb protection 
by removable brace with intermittent, gentle passive mobilization under 
strict supervision Gradual weight bearing after radiological evidence of 
union. 
 
Follow up 
 
I. Clinical (a) Subjective criteria for either limb 
 
     1. Pain 
 
    2. Function 
 
    3. Emotional acceptance 
 
   (b) Objective criteria specific for the lower extremity 
 
    1. Walking ability 
 
    2. Gait 
 
    3. Supports 
 
II Radiological 
 
 a. Presence of lysis more than 5 mm 
 
 b. Complete sclerotic margin all around the cement 
 
 c. Union or consolidation of bone graft. 
 
Complications 
 
 1. Infection 
 
 2. Wound complications 
 
 3. Pathological Fracture 
 
 4. Neurovascular Complications 
 
 5. Secondary osteoarthritis 
 
  6. Recurrence 
 
 7. Joint Stiffness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CASE REPORTS  
      CASE 1 (  Mr.Rambabu ) 
                   26 year old man  came with complaints of  pain in left knee 2 
months duration. History of similar  illness 8 months back,diagnosed as 
GCT Left proximal tibia and treated by curettage and bone cement. 
                   On  examination surgical scar and tenderness present over the 
left proximal tibia. X ray showed  area of  lysis between bone cement and 
bone indicative of  recurrent GCT. 
                   FNAC suggestive of GCT  
          Treated by bone cement removal,extended curettage with 
Hydrogen peroxide  and cavity was filled with bone cement. 
                    2 year and 4 months follow up patient clinically and 
radiologically  disease free. 
 
 
 
 
 
  
CASE 2  (Visalatchi)  
        A 19 year  old female came with complaints of pain and swelling in 
the left knee of 8 months duration. 
        On examination bony swelling and tenderness  present in the distal 
femur. Knee movements were painful and restricted. 
        X ray showed eccentric osteolytic lesion in the epiphysio- 
metaphyseal region of the distal femur with pathological fracture. 
        FNAC suggestive of GCT  
        Treated with extended curettage with hydrogen peroxide and cavity 
filled with bone cement. 
         At  2 year and 4 months follow up   patient is disease free. Available 
 range of movement in the knee is 0 to 100 degrees. 
 
 
 
 
 
     
   CASE 3  (Helena)  
        A 17 year  old female came with complaints of pain and swelling in 
the left knee of 6 months duration. 
        On examination bony swelling and tenderness  present in the 
proximal tibia. Knee movements were painful and restricted. 
        X ray showed eccentric osteolytic lesion in the epiphysio- 
metaphyseal region of the proximal tibia with pathological fracture. 
        FNAC suggestive of GCT  
        Treated  with extended curettage with hydrogen peroxide and cavity 
filled with fibular strut graft,cancellous iliac bone graft ,G-bone and bone 
cement. 
         At  2 year and  follow up   patient is disease free. Available  range 
of movement in the knee is 0 to 110 degrees. 
 
 
 
 
  
CASE 4  (Kotteswara Rao)  
        A 30 year  old male came with complaints of pain and swelling in 
the left knee of 8 months duration. 
        On examination bony swelling and tenderness  present in the distal 
femur. Knee movements were painful and restricted. 
        X ray showed eccentric osteolytic lesion in the epiphysio- 
metaphyseal region of the distal femur with pathological fracture. 
        FNAC suggestive of GCT  
        Treated with extended curettage with hydrogen peroxide and cavity 
filled with  fibular strut graft,cancellous iliac bone graft ,G-bone and bone 
cement. 
         At  2 year follow up   patient is disease free. Available  range of 
movement in the knee is 0 to 90 degrees. 
 
 
 
 
  
RECURRENT GCT 
 
       Case 1                                                                      AFTER 2 MONTHS OF  
 
 
               INITIAL PROCEDURE, 
        CURETTAGE & BONE CEMENT 
 
 
 
SUBSTITUTE PROCEDURE-CEMENT REMOVAL, EXTENDED CURETTAGE & BONE 
CEMENT 
  
Case -2 
AGGRESSIVE GCT WITH PATHOLOGICAL FRACTURE - FEMUR 
 
                                                                   PRE-OP 
 
  
 
 
LESION AFTER EXPOSURE  
 
 
 
     THE CAVITY BEFORE CURETTAGE  
 
 
 
 
           USING H2O2 AS ADJUVANT                                            CURETTED   
                                                                                                                     MATERIAL 
 
  
 
 
 PLACING FIBULAR STRUT GRAFT                                                         WITH BONE  
                                                                                                                                 CEMENT 
 
 
         IMMEDIATE POST- OP                                                           ONE-MONTH FOLLOW-UP 
 
 
                                                                               FOLLOW-UP 
                                   3 MONTHS                                                                            4 MONTHS 
 
 
 
 
7 MONTHS FOLLOW-UP 
 
 
 
22 MONTHS FOLLOW-UP 
 
 
Case -3 
 
AGGRESSIVE GCT WITH PATHOLOGICAL FRACTURE – TIBIA 
 
PRE-OP 
 
 
 
 
 
 
 
 
 
                CT SHOWING THE BREACH                                         LESION AFTER EXPOSURE 
 
 
 
 
                IMMEDIATE POST-OP                                                   2 MONTHS FOLLOW-UP[ 
 
 
3 MONTHS FOLLOW-UP 
 
 
6 MONTHS FOLLOW-UP 
 
 
 
14 MONTHS FOLLOW-UP 
 
 
                                                   14 MONTHS FOLLOW-UP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 4 
 
AGGRESSIVE GCT WITH PATHOLOGICAL FRACTURE – FEMUR 
 
PRE-OP 
  
 
 
 
 
 
 
 
 
 
 
 
PRE-OP 
 
 
LESION AFTER EXPOSURE 
 
 
                  CURETTED MATERIAL                                              CAVITY AFTER  
                                                                                                                    CURETTAGE 
 
 
 
 
 CAVITY SHOWING PATHOLOGICAL FRACTURE            HARVESTED NON-VASCULARISED  
                                                                                                                      FIBULAR STRUT GRAFT 
 
 
PLACEMENT OF FIBULAR STRUT GRAFT             CAVITY FILLED WITH G BONE AND  
                                                                                                         CANCELLOUS BONE GRAFT 
 
 
 
 
 
BONE STABILISED WITH BONE CEMENT                                                  IMMEDIATE  
                                                                                                                                       POST-OP 
 
 
 
 
 
 
 
 
 
MICROSCOPIC PICTURE 
